Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 788 participants.

Also called NCT03136484

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 788 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03136484
  • EudraCT 2016-000989-35
Other papers using this trial's data
  • Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia, 2020-03 DOI, PubMed 31897524, PMC6997246 In the PMC Open Access subset under CC BY.
  • Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial The lancet. Diabetes & endocrinology, 2019-11 DOI, PubMed 31540867

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Canada, India, Ireland, Italy, Lebanon, Malaysia, Mexico, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03136484. Randomized; double masking; primary purpose treatment. Start 2017-03-15 (actual); primary completion 2018-10-16 (actual). Results posted on 2019-12-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Acronym
SUSTAIN 8
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo (canagliflozin)
Intervention (Drug)
Placebo (semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03136484
Content hash
8608262651f7d39e006b5afba7bd50acfb9b2e2fa66f1b69084c9699fa4683f4